April 4, 2013
, former CEO of Apple, and
, former counsel to PayPal, both on the Board of Directors of Galectin Therapeutics (NASDAQ: GALT) authored an opinion piece in today's
Atlanta Journal Constitution
discussing the future of
as the emerging Silicon Valley for changing the world by curing the big diseases, and why they moved Galectin Therapeutics to
"The world needs a biotech Silicon Valley. We believe that
is perfectly poised to become just that," wrote Amelio and Martin.
To read the full op-ed from the
. To schedule interviews with
, please contact
, or (202) 257-4638.
About Galectin Therapeutics
Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at
SOURCE Galectin Therapeutics Inc.